PlainPharmaWatch

CMS Open Payments · Program Year 2024

Genentech USA, Inc.

Genentech USA, Inc. reported $8,490,818.06 across General Payments, Research, and Ownership to 55,859 physicians and teaching hospitals across 55,859 transactions.

See the rankings → How this is sourced
$8.5M
All-tracks total
55,859
Transactions
55,859
Recipients
−$1.0M
General Payments vs PY2023

Genentech USA, Inc. reported $8,490,818.06 across all CMS Open Payments tracks (General + Research + Ownership) to 55,859 physicians and teaching hospitals in Program Year 2024 - ranking #200 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $8,490,818.06, averaging $152.00 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer genentech-usa-inc Genentech USA, Inc.

$8.5M · #200/1,925 · 0.1% industry · PY2024

  • TOT $8.5M
  • RANK #200
  • SHARE 0.1%
  • TXN 55,859
  • RCP 55,859
  • CAT 6
  • GEN $8.5M
  • ΔGEN −$1.0M
  • TOP1 1.2%
  • PY 2024

Volume peers

Nearest volume peer: Circinus Medical Technology LLC ($8.5M)

Indivior Inc.$8.6MShoulder Innovations, Inc.$8.5MCircinus Medical Technology …$8.5MGenentech USA, Inc. (this)$8.5MBavarian Nordic A/S$8.4M
All-tracks payment totals near Genentech USA, Inc. (CMS Open Payments PY2024)

Genentech USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Genentech USA, Inc.'s CMS-reported General Payments decreased by $1.0M (−11.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: GENENTECH USA, INC.PY2023: GENENTECH USA, INC.PY2024: Genentech USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$9.5MPY2024$8.5M
PY2023
$9,540,660.65
PY2024
$8,490,818.06

What the Data Shows for Genentech USA, Inc.

Rank #200 of 1,925 companies in CMS Open Payments for 2024 belongs to Genentech USA, Inc., which reported $8,490,818.06 across 55,859 transactions to 55,859 recipients - a comparatively small 0.1% slice of all industry payments reported nationwide for the year. Averages work out to $152.00 per transaction and $152.00 per recipient.

"Consulting Fee" leads the 6-category general-payment breakdown below at $2.9M (34.7% of General Payments, 822 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Consulting Fee" leads Genentech USA, Inc.'s 6-category general-payment breakdown at $2.9M, 34.7% of the reported total.

Genentech USA, Inc. reports 6 general-payment categories - the top three are Consulting Fee (34.7%), Compensation for Services Other Than Consulting (29.5%), and Food and Beverage (17.9%). The remaining 3 categories make up 17.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Genentech USA, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$2.9M2. Compensation for Services…$2.5M3. Food and Beverage$1.5M4. Space Rental or Facility …$781.7K5. Travel and Lodging$649.7K6. Grant$85.0K
Payment Type Amount Transactions
Consulting Fee $2.9M 822
Compensation for Services Other Than Consulting $2.5M 662
Food and Beverage $1.5M 52,372
Space Rental or Facility Fees $781.7K 174
Travel and Lodging $649.7K 1,826
Grant $85.0K 3

Recipient Concentration in General Payments

The five largest recipient relationships account for $396,824.89 (4.7%) of $8,490,818.06 in this company's General Payments records across 21,711 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Genentech USA, Inc.

The five named recipients with the highest reported General Payments from this company

The Nebraska Medical Center$100.0KUniversity Of Alabama Hospit…$100.0KScott Commins$75.0KUt Md Anderson Cancer Center$70.0KJoseph Nezgoda$51.9K
  1. 1

    The Nebraska Medical Center

    $100,000.00 across 1 reported transactions

  2. 2

    University Of Alabama Hospital

    $100,000.00 across 1 reported transactions

  3. 3

    Scott Commins

    $74,957.47 across 68 reported transactions

  4. 4

    Ut Md Anderson Cancer Center

    $70,000.00 across 1 reported transactions

  5. 5

    Joseph Nezgoda

    $51,867.42 across 41 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Genentech USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Genentech USA, Inc..

Seagen Inc.

HHI 20

Valinor Pharma, LLC

HHI 20

Orexo US, Inc.

HHI 20

Regeneron Healthcare Solutions, Inc.

HHI 19

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Genentech USA, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Genentech USA, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.